A First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs LY 3305677 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 21 Jul 2017 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Planned End Date changed from 14 Jun 2017 to 14 Jul 2017.
- 19 Jun 2017 Planned primary completion date changed from 14 Jun 2017 to 14 Jul 2017.